<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753036</url>
  </required_header>
  <id_info>
    <org_study_id>EA4/069/14</org_study_id>
    <nct_id>NCT02753036</nct_id>
  </id_info>
  <brief_title>Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer</brief_title>
  <acronym>CICARO</acronym>
  <official_title>Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer (CICARO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurotoxic phenomena are among the most common and difficult to treat side effects of&#xD;
      chemotherapy. The development of chemotherapy induced peripheral neuropathy (CIPN) is a&#xD;
      well-recognized adverse reaction in the peripheral nervous system. Side effects of&#xD;
      chemotherapy in the central nervous system, however, particularly changes of cognitive&#xD;
      function (in non-medical literature referred to as &quot;chemobrain&quot;) are diffuse and difficult to&#xD;
      attribute to individual cytostatic drugs. The primary purpose of this study is to assess&#xD;
      cognitive function in patients with ovarian and breast cancer before and after systemic&#xD;
      chemotherapy with paclitaxel with standardized neuropsychological tests and compare the&#xD;
      outcome to patients with benign gynecological tumors and breast cancer without chemotherapy&#xD;
      treatment, respectively. Secondary parameters include the assessment of olfactory function,&#xD;
      total neuropathy score and cytokine profiles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary outcome parameter:&#xD;
&#xD;
      compound score of standardized neuropsychological test&#xD;
&#xD;
      Secondary parameters:&#xD;
&#xD;
        -  olfactory function (Sniffin Sticks)&#xD;
&#xD;
        -  total neuropathy score (TNS), reduced version (clinical examination, neurography of&#xD;
           sural and peroneal nerve)&#xD;
&#xD;
        -  cytokine profiling from serum samples (ELISA)&#xD;
&#xD;
        -  quality of life (questionnaire)&#xD;
&#xD;
        -  depression screening (questionnaire)&#xD;
&#xD;
        -  symptoms of polyneuropathy (questionnaire)&#xD;
&#xD;
        -  symptoms of cognitive impairment (everyday memory test questionnaire)&#xD;
&#xD;
      Assessment time points:&#xD;
&#xD;
        -  baseline (after surgical tumor resection and before chemotherapy)&#xD;
&#xD;
        -  follow up 1 (3 weeks after last chemotherapy cycle or 21 weeks (control patients))&#xD;
&#xD;
        -  follow up 2 (optional; 1 year after chemotherapy completion)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline compound score of standardized neuropsychological test</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>standardized neuropsychological test covering verbal memory, visual-spatial memory, short term/ working memory, executive functions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline olfactory function</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>standardized test battery (Sniffin Sticks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline total neuropathy score (TNSr)</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>reduced version includes clinical examination and neurography of sural and peroneal nerve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline cytokine profiling (serum sample)</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>ELISA of serum samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline quality of life questionnaire</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>EORTC-QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline depression screening questionnaire</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>DESC-I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline symptoms of polyneuropathy questionnaire</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>EORTC-QLQ-C30+CIPN20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline symptoms of cognitive decline (questionnaire)</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>everyday memory test</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">72</enrollment>
  <condition>Cognition Disorders</condition>
  <condition>Polyneuropathies</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <description>patients with ovarian cancer and paclitaxel + carboplatin combination chemotherapy as well as patients with breast cancer and paclitaxel +/- carboplatin combination chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <description>patients with benign gynecological tumors after laparoscopic surgical resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tumor control</arm_group_label>
    <description>patients with breast cancer with anti-hormonal and/or localized radiation treatment but no chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>standard combination chemotherapy (paclitaxel +/- carboplatin) if necessary according to treatment guidelines</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum samples, PBMC&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic, department of gynecology&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  Karnofsky index &gt;70% / ECOG &lt;1&#xD;
&#xD;
          -  at least 8 years of education&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  post surgical delirium&#xD;
&#xD;
          -  major depression&#xD;
&#xD;
          -  alcohol or drug abuse&#xD;
&#xD;
          -  anemia &lt; 8 g/dl&#xD;
&#xD;
          -  mild cognitive impairment or dementia&#xD;
&#xD;
          -  previous neurotoxic chemotherapy treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra Huehnchen, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Petra Huehnchen</investigator_full_name>
    <investigator_title>resident and postdoctoral fellow</investigator_title>
  </responsible_party>
  <keyword>cognition</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>polyneuropathy</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>cancer</keyword>
  <keyword>chemobrain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

